Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.10) by 0.91 percent. This is a 263.33 percent decrease over losses of $(0.30) per share from the same period last year.
Spot Bitcoin ETFs See $223M Net Outflows On Monday
Bitcoin‘s (CRYPTO: BTC) strong start to the week hit a road bump after Monday’s trading data showed that interest in spot ETFs appears to be cool
